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Abstract
The neuropeptide galanin is widely expressed in both the central and peripheral nervous systems and is involved
in many diverse biological functions. There is a substantial data set that demonstrates galanin is upregulated after
injury in the DRG, spinal cord and in many brain regions where it plays a predominantly antinociceptive role in
addition to being neuroprotective and pro-regenerative. To further characterise the role of galanin following nerve
injury, a novel transgenic line was created using the binary transgenic tet-off system, to overexpress galanin in
galaninergic tissue in a suppressible manner. The double transgenic mice express significantly more galanin in the
DRG one week after sciatic nerve section (axotomy) compared to WT mice and this overexpression is suppressible
upon administration of doxycycline. Phenotypic analysis revealed markedly attenuated allodynia when galanin is
overexpressed and an increase in allodynia following galanin suppression. This novel transgenic line demonstrates
that whether galanin expression is increased at the time of nerve injury or only after allodynia is established, the
neuropeptide is able to reduce neuropathic pain behaviour. These new findings imply that administration of a
galanin agonist to patients with established allodynia would be an effective treatment for neuropathic pain.
Findings
The 29 (30 in human) amino acid neuropeptide galanin
has a wide distribution in both the peripheral and cen-
tral nervous systems. The galanin peptide shares homol-
ogy with only two other known peptides, galanin-like
peptide (GALP) [1] and the GALP splice variant alarin
[2]. Galanin is expressed at low levels in ~5% of small
diameter C-fibre neurons in the intact adult rodent dor-
sal root ganglia (DRG) [3-5]. Higher levels of the pep-
tide are detected in the primary afferent terminals of the
spinal cord (lamina II), the dorsal horn inter-neurons
[6], and in a number of brain regions known to modu-
late nociception, including the arcuate nucleus and peri-
aqueductal grey [7,8]. Galanin levels are strongly and
persistently increased in the DRG and dorsal horn of
the spinal cord as well as in many regions of the central
nervous system following nerve injury. Axotomy of
motor nerves elevates galanin mRNA levels by 6-10 fold
in the dorsal motor nucleus of the vagus and nucleus
ambiguus [9] and a similar increase is found in the facial
nucleus following facial nerve axotomy [10]. Galanin
levels in the central nervous system are also upregulated
in many disease states and in rodent models of these
pathological conditions, including Alzheimer’sd i s e a s e
[11], stroke induced ischemia [11,12] and in multiple
sclerosis [13]. However, the most potent upregulation
occurs in the DRG following peripheral nerve axotomy
when galanin is rapidly up-regulated by up to 120-fold
and is expressed in 40-50% of sensory neurons [14]. A
much smaller increase in galanin expression is observed
in the dorsal horn after peripheral nerve injury [15]
implying that much of the neuropeptide is anterogradely
transported to the site of injury. Following the descrip-
tion of galanin expression increasing after nerve injury,
the role of galanin in nociception and neuropathic pain
has been the subject of a substantial body of research.
Studies of intact and nerve injured animals have
described a bell-shaped response curve after intrathecal
infusion of galanin and galanin agonists [16-18] with
inhibition of nociceptive responses at high doses [19,20].
To further define the role played by galanin in nocicep-
tion, we have previously generated and characterised
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nin in the DRG after nerve injury [21] or constitutively
and ectopically in both the intact DRG and after nerve
injury [22]. Both lines demonstrate a marked reduction
in mechanical allodynia in the spared nerve injury (SNI)
model of neuropathic pain [22]. Subsequently, another
galanin over-expressing mouse line that ectopically
over-express galanin in the DRG under the control of
the dopamine beta-hydroxylase promoter has shown a
similar decrease in neuropathic pain-like behaviour [23].
Whilst the study of these existing transgenic lines have
generated valuable data, they all overexpress galanin
embryonically and throughout the animals life. It is
therefore desirable to reversibly overexpress galanin in a
temporally controllable fashion allowing one to study
whether galanin can reverse established allodynia, thus
validating galanin as a target for drug discovery.
To further define the role of galanin in the nervous
system after nerve injury, we have used the tet-off sys-
tem to develop a binary galanin overexpressing mouse
line in which the overexpression can be suppressed by
administration of the tetracycline analogue doxycycline
(dox). Two transgenes were generated both utilising pre-
viously described constructs from the murine galanin
gene. In order to direct galanin overexpression solely to
galaninergic tissue, the previously characterised 20 kb
galanin enhancer [21,24] was used to drive tetracycline
controlled transactivator (tTA) expression (termed tTA
transgene). In parallel, the 4.6 kb galanin genomic locus,
containing all 6 exons which has previously been shown
to direct high levels of gal a n i ni nan u m b e ro ft r a n s -
genic lines [22], was inserted downstream of the tetracy-
cline operator (tetO) sequences (termed tetO transgene).
Three founder lines were characterised for each trans-
gene. The increase in tTA mRNA expression was mea-
sured in the DRG after axotomy of the sciatic nerve in
each of the tTA lines using quantitative real-time PCR
(Figure 1A). Line tTA176 had a significant increase in
mRNA levels after axotomy. The tetO lines were
assessed for the level of basal expression in the absence
of the transactivator protein, so called “leakiness” (Fig-
ure 1B). Quantitative real-time PCR revealed that line
tetO21 had a significant degree of basal expression. The
tTA line with the greatest axotomy response (line 176)
and the tetO line that displayed the lowest level of basal
expression (line 82) were subsequently crossed to each
other to generate a double heterozygous transgenic line.
The level of galanin overexpression in the double het-
erozygous transgenic was assessed at the protein level
by measuring the percentage of galanin positive neurons
in the DRG one week after axotomy, both in the pre-
sence and absence of dox (Figure 2). An approximate
50% increase was observed in the number of galanin
positive neurons in the DRG of the double transgenic
line compared to WT animals. This overexpression was
abolished by administering 200 mg/ml of dox in the
drinking water from the time of sciatic nerve axotomy
until the animals were sacrificed one week later. Dox
administration had no effect on the levels of galanin
protein in WT animals. To assess the functional activity
of transgene-derived galanin protein, mechanical with-
drawal thresholds were measured following the SNI
model of neuropathic pain in adult double heterozygous
transgenic and WT mice (Figure 3). Mechanosensory
thresholds (using von Frey hairs) were measured first in
intact animals and then following SNI over a 35 day
period consisting of 14 days with no dox, then 7 days
on dox, followed by a further 14 days with no dox. The
comparison of the double transgenic to WT mice
revealed significant differences in the levels of allodynia
over the course of the experiment. Allodynia was signifi-
cantly attenuated after SNI in the double heterozygous
transgenic in the absence of dox when compared to WT
controls from day 3 to day 14. This finding is consistent
Figure 1 Quantitative real-time PCR analysis of tTA and tetO lines. Real-time quantitative PCR was used to measure: A, the fold increase in
the level of tTA mRNA in pooled DRG samples one week after axotomy. Line 176 has significantly higher levels of tTA mRNA than tTA9 and
tTA17 which do not differ significantly from each other or WT mice. B, expression of total galanin mRNA in pooled DRG samples from intact
transgenic and WT mice were compared. Line tetO21, tetO36 and tetO82 were increased by 5.36, 1.69 and 1.44-fold respectively. Line tetO21
was significantly different to the other 2 lines (1-way ANOVA, *** denotes P < 0.001).
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mice, which used the same 20 kb and 4.6 kb constructs
used in this study [22]. The withdrawal thresholds of
t h ed o u b l et r a n s g e n i cw e r en o ts i g n i f i c a n t l yd i f f e r e n tt o
WT animals following the administration of dox, as the
mice became more allodynic suggesting that dox suc-
cessfully suppresses transgene-derived galanin. Following
the withdrawal of dox, there was an increase in withdra-
wal thresholds over the next seven days, presumably due
to the animals metabolising and clearing the dox thus
allowing the levels of transgene-derived galanin to rise
once again.
The generation of the double transgenic mice address
one of the fundamental drawbacks of conventional trans-
genic overexpression, that of not being able to separate
and independently study the role of a gene during devel-
opment from its role in the adult. Having reversible and
temporal control over gene expression allows the
Figure 2 Percentage of galanin positive DRG neurons in double transgenic lines after axotomy.A ,R e p r e s e n t a t i v eD R Gs e c t i o n s
immunohistochemically stained for galanin one week after sciatic nerve axotomy from double transgenic and WT control. Animals were given
water (including 5% w/v sucrose) (top panel) or dox (including 5% w/v sucrose) from the time of axotomy until sacrifice (lower panel). B, The
percentage of galanin positive neurons in sections from axotomised L4 and L5 DRG with dox at 200 mg/ml (hatched bar) and without dox
(solid bar). Double transgenic DRG have a significant overexpression of galanin after axotomy when compared to WT control animals in the
absence of dox. No significant differences between transgenic and WT mice were observed when dox was administered (1-way ANOVA ***
denotes P < 0.001).
Figure 3 Mechanical withdrawal threshold responses of double transgenic and WT mice after SNI model of neuropathic pain. Baseline
(BL) recordings were taken before SNI. After surgery, the animals received no dox for 14 days, then dox for 7 days followed by a further 14 days
with no dox. Pre-surgery thresholds were not significantly different between genotypes. The WT group developed robust allodynia and this was
not affected by the administration of dox. Double transgenic mice developed significantly less allodynia than WT controls between days 3 and
14 of the first “off dox” period. No significant difference between the genotypes was observed from day 2 to 7 of the “on dox” period but a
significant difference was again observed by day 7 of the second “off dox” period (2-way ANOVA. * denotes P < 0.05, ** denotes P < 0.01 and
*** denotes P < 0.001).
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roles played by a protein in the adult, as compared to the
study of animals that overexpress during embryogenesis
and throughout the entire life of that animal. These find-
ings demonstrate that the double transgenic line overex-
presses galanin in the DRG after sciatic nerve injury and
that the overexpression is abolished by dox administra-
tion. Further, the level of overexpression is sufficient to
significantly attenuate allodynia following SNI. These
mice also present a means to potentially rescue the devel-
opmental DRG nociceptor losses described in the galanin
knockout and thus potentially allow, for the first time,
the characterisation of a developmentally normal adult
that is null for galanin. Furthermore, the finding that
galanin can significantly attenuate established allodynia




Transgenic mice (CBA/B6 strain) were generated that
expressed a) tTA (pTet-tTak - Invitrogen, Paisley, UK)
under the control of the previously characterised 20 kb
galanin enhancer region [21,24] and b) the 4.6 kb galanin
genomic locus [22] under the control of the tetO
sequences. Founder mice were initially identified by
southern blot using 1.2 kb NcoI-XhoI and 1.9 kb EcoRI-
BamHI probes, both probes being excised form the gala-
nin genomic locus, to identify tTA and tetO positive
founder mice respectively. Genomic DNA was digested
with EcoRI (tTA) and EcoRI + XhoI (tetO). Subsequent
genotyping was carried out by PCR using primers 5’-
TTTTGACCTCCATAGAAGACACC-3’ and 5’-ATGG
TAGCGTCAGACGTCCG-3’ to detect tetO and primers
5’-GAGTATGGTGCCTATCTAACATCT-3’ and 5’-
GACTGTGGGTGATCCTCTCC-3’ to detect tTA. A
band from the endogenous galanin gene is also amplified
by these primers as an internal control.
The double transgenic mice were generated by crossing
line tetO176 and line tTA82 line. In all experiments, dou-
ble heterozygote transgenic and WT animals that were
age, sex and strain matched were compared and tested
with the genotype blind to the experimenter. All surgery
and procedures were carried out in accordance with the
United Kingdom Animal Scientific Procedures Act 1986.
RT-PCR and Quantitative real-time PCR
Total RNA extraction, DNAse treatment and re-extrac-
tion and reverse transcription are as previously
described [25]. Quantitative real-time PCR was per-
formed as previously detailed [26]. The forward primer,
reverse primer and internal non-extendable fluorescent
probe for tetO and tTA mRNA are detailed below. tetO
forward 5’-ACGCTGTTTTGACCTCCATAGAA-3’,
reverse 5’-TGGCGGGCTGGATGGT-3’, probe 5’-
CGGGACCGATCCAGCCTCCG-3’.t T Af o r w a r d5 ’-
GATAAAAGTAAAGTGATTAACAGCGCATT-3’,
reverse 5’-CTAGCTTCTGGGCGAGTTTACG-3’,p r o b e
5’-ACCTTCGATTCCGACCTCATTAAGCAGCT-3’.
Mouse surgery, immunohistochemistry and behavioural
analysis
Sciatic nerve axotomy, SNI, measurement of mechanical
withdrawal thresholds and immunohistochemistry are as
previously described [22,24,27]. Where appropriate, ani-
mals (WT and transgenics) were given 200 mg/ml of
dox (Sigma) in the drinking water. 5% (w/v) sucrose was
included in all drinking water to mask the bitter taste of
the antibiotic if present.
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